Predictive value of APOE genotyping in incipient Alzheimer's disease

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The Mayo Alzheimer's Disease Center/Alzheimer's Disease Patient Registry is a prospective, longitudinal project of aging and dementia in a community setting. Over 400 pairs of individuals have been studied through this project, and extensive data on clinical, radiological, neuropathological, and biological variables have been gathered. Previous case-control studies on this group of subjects have documented the role of the apolipoprotein E (APOE) ε4 as a risk factor for dementia. Subsequent analyses between APOE and the age of the patients with dementia have shown that most of the ε4 effect is manifest in subjects under 75 years of age. We have also used this patient resource to study a group of individuals who are at risk for dementia by virtue of having a significant memory impairment. We have designated these patients as having a mild cognitive impairment because they have abnormal memory function but do not reach criteria for dementia. Over the course of several years of follow-up, these subjects evolve to dementia at a rate of approximately 15% per year. The presence of an APOE ε4 carrier status is the best predictor of subsequent development of dementia in these individuals. These studies indicate that APOE is an important risk factor for AD, and in patients with a mild cognitive impairment, APOE may be useful in predicting who is likely to progress to dementia.

Original languageEnglish (US)
Pages (from-to)58-69
Number of pages12
JournalAnnals of the New York Academy of Sciences
Volume802
DOIs
StatePublished - 1996

Fingerprint

Apolipoproteins E
Apolipoprotein E4
Dementia
Alzheimer Disease
Data storage equipment
Aging of materials
Alzheimer's Disease
Registries
Case-Control Studies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Predictive value of APOE genotyping in incipient Alzheimer's disease. / Petersen, Ronald Carl; Waring, Stephen C.; Smith, Glenn E.; Tangalos, Eric George; Thibodeau, Stephen N.

In: Annals of the New York Academy of Sciences, Vol. 802, 1996, p. 58-69.

Research output: Contribution to journalArticle

@article{650a0c14ad12426cb8f9c87a938afeed,
title = "Predictive value of APOE genotyping in incipient Alzheimer's disease",
abstract = "The Mayo Alzheimer's Disease Center/Alzheimer's Disease Patient Registry is a prospective, longitudinal project of aging and dementia in a community setting. Over 400 pairs of individuals have been studied through this project, and extensive data on clinical, radiological, neuropathological, and biological variables have been gathered. Previous case-control studies on this group of subjects have documented the role of the apolipoprotein E (APOE) ε4 as a risk factor for dementia. Subsequent analyses between APOE and the age of the patients with dementia have shown that most of the ε4 effect is manifest in subjects under 75 years of age. We have also used this patient resource to study a group of individuals who are at risk for dementia by virtue of having a significant memory impairment. We have designated these patients as having a mild cognitive impairment because they have abnormal memory function but do not reach criteria for dementia. Over the course of several years of follow-up, these subjects evolve to dementia at a rate of approximately 15{\%} per year. The presence of an APOE ε4 carrier status is the best predictor of subsequent development of dementia in these individuals. These studies indicate that APOE is an important risk factor for AD, and in patients with a mild cognitive impairment, APOE may be useful in predicting who is likely to progress to dementia.",
author = "Petersen, {Ronald Carl} and Waring, {Stephen C.} and Smith, {Glenn E.} and Tangalos, {Eric George} and Thibodeau, {Stephen N}",
year = "1996",
doi = "10.1111/j.1749-6632.1996.tb32599.x",
language = "English (US)",
volume = "802",
pages = "58--69",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Predictive value of APOE genotyping in incipient Alzheimer's disease

AU - Petersen, Ronald Carl

AU - Waring, Stephen C.

AU - Smith, Glenn E.

AU - Tangalos, Eric George

AU - Thibodeau, Stephen N

PY - 1996

Y1 - 1996

N2 - The Mayo Alzheimer's Disease Center/Alzheimer's Disease Patient Registry is a prospective, longitudinal project of aging and dementia in a community setting. Over 400 pairs of individuals have been studied through this project, and extensive data on clinical, radiological, neuropathological, and biological variables have been gathered. Previous case-control studies on this group of subjects have documented the role of the apolipoprotein E (APOE) ε4 as a risk factor for dementia. Subsequent analyses between APOE and the age of the patients with dementia have shown that most of the ε4 effect is manifest in subjects under 75 years of age. We have also used this patient resource to study a group of individuals who are at risk for dementia by virtue of having a significant memory impairment. We have designated these patients as having a mild cognitive impairment because they have abnormal memory function but do not reach criteria for dementia. Over the course of several years of follow-up, these subjects evolve to dementia at a rate of approximately 15% per year. The presence of an APOE ε4 carrier status is the best predictor of subsequent development of dementia in these individuals. These studies indicate that APOE is an important risk factor for AD, and in patients with a mild cognitive impairment, APOE may be useful in predicting who is likely to progress to dementia.

AB - The Mayo Alzheimer's Disease Center/Alzheimer's Disease Patient Registry is a prospective, longitudinal project of aging and dementia in a community setting. Over 400 pairs of individuals have been studied through this project, and extensive data on clinical, radiological, neuropathological, and biological variables have been gathered. Previous case-control studies on this group of subjects have documented the role of the apolipoprotein E (APOE) ε4 as a risk factor for dementia. Subsequent analyses between APOE and the age of the patients with dementia have shown that most of the ε4 effect is manifest in subjects under 75 years of age. We have also used this patient resource to study a group of individuals who are at risk for dementia by virtue of having a significant memory impairment. We have designated these patients as having a mild cognitive impairment because they have abnormal memory function but do not reach criteria for dementia. Over the course of several years of follow-up, these subjects evolve to dementia at a rate of approximately 15% per year. The presence of an APOE ε4 carrier status is the best predictor of subsequent development of dementia in these individuals. These studies indicate that APOE is an important risk factor for AD, and in patients with a mild cognitive impairment, APOE may be useful in predicting who is likely to progress to dementia.

UR - http://www.scopus.com/inward/record.url?scp=0030450730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030450730&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.1996.tb32599.x

DO - 10.1111/j.1749-6632.1996.tb32599.x

M3 - Article

VL - 802

SP - 58

EP - 69

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -